The EUCLID Study (Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease)

Abstract

In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel in the reduction of cardiovascular events during a 30-month follow-up period; the only significant difference between the groups was in the rate of ischemic stroke. The rates of major bleeding were similar among the patients in the two trial groups.